Summary: These investigations characterised the cere brovascular effects of an endothelin ETA-receptor antag onist PD I 56707 in normal and ischaemic cat brain. A dose of PD 156707 that inhibited the effects of exogenous en dothelin-I was established in nonischaemic cerebral re sistance arterioles. Perivascular microapplication of the endothelin-receptor antagonist PD 156707 (0.03-3 I-lM) had a minimal effect on nonischaemic pial resistance ar terioles. The perivascular coapplication of PD I 56707 and ET -1 (10 nM) effected a dose-dependent attenuation of the ET-I vasoconstrictive response (lC5o = 0.1 I-lM). In travenous administration of PDI56707 (3 I-lmol/kg bolus + 5 I-lmol/kg/h infusion) attenuated the vasoconstriction elicited by perivascular ET-I (10 nM) in normal pial ar terioles (ET-I vasoconstriction: -37 ± 13% from prein jection baseline; after intravenous PD156707: 6 ± 10% from preinjection baseline). In the focal ischaemia stud ies, cerebral perfusion was measured in the suprasylvian Pharmacotherapy of cerebral ischaemia has two general approaches. First, pharmacologic interven tions are directed at various points in the cascade of neurochemical events that lead to neuronal damage [e.g., N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-methylisoxazole propionate (AMPA)-
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receptor antagonists, glutamate release inhibitors, nitric oxide synthase inhibitors, free radical scav engers and the inhibition of the effects of the cyto kines (Rothwell and Relton, 1993; Gill, 1994; Muir and Lees, 1994; Phillis, 1994) . Second, pharmaco logic interventions are directed at removing the pri mary intraluminal obstruction [e.g., tissue plasmin ogen activator (TPA)] or at reducing the vasocon strictor influences on collateral vessels to the tissue at risk [e.g., L-type calcium channel antagonists (Kazda et aI., 1982; Fisher and Grotta, 1993; Over gaard, 1994) ].
The endothelins are a family of 21 amino acid peptides and are potent constrictors of vascular smooth muscle. The vascular effects of the endo thelins are mediated by two receptor subtypes, en dothelin-A (ETA)' which are vasoconstrictor, and endothelin-B (ET B), which are vasodilator (Masaki et aI., 1994) . The application of exogenous ET-l results in marked constrictions of cerebral vessels in vivo and in vitro Salom et aI., 1993; Feger et aI., 1994) . Topical or intraparenchymal application of exogenous ET-l on cerebral blood vessels is associated with suffi cient reductions in the CBF to cause irreversible ischaemic brain damage (Robinson et aI. , 1990; Fuxe et aI., 1992; Macrae et aI. , 1993; Sharkey et aI., 1993) . Increases in endogenous endothelin lev els have been reported after focal cerebral isch aemia in tissue and plasma (Ziv et aI., 1992; Viossat et aI., 1993; Barone et aI. , 1994) . Our own investi gations demonstrated an increase in endothelin mediated vascular tone in cerebral arterioles in the penumbra after a focal cerebral ischaemic challenge (Patel et aI., 1995a) .
The recent availability of nonpeptide low molecular-weight endothelin antagonists, such as Bosentan, that penetrate the blood-brain barrier have enhanced the interest in the physiologic and pathophysiologic role of the endothelins in the ce rebral circulation (Clozel et aI. , 1994; Patel et aI., 1994) . Recently a new group of nonpeptide endo thelin antagonists (butenolides) have been devel oped, with PD156707 the most potent and selective for the ETA receptor (Doherty et aI. , 1995) .
The aims of these investigations were threefold. First, the cerebrovascular effects of the endothelin receptor antagonist PD 1 56707 were characterised in the nonischaemic brain to identify a dose of the antagonist, administered intravenously, that would inhibit the vasoconstrictor effect of exogenous ET I. Second, the ability of the validated dose of PD156707 to alter cerebral perfusion (measured by laser Doppler flowmetry) in the ischaemic penum bra was assessed after permanent middle cerebral artery (MCA) occlusion in the cat. Third, the ability of the validated dose of PD156707 to reduce the volume of ischaemic damage after permanent focal cerebral ischaemia in the cat was assessed in the animals in which cerebral perfusion had been mea sured.
MATERIALS AND METHODS

General surgical preparation
The experiments were performed on 14 adult fe male cats weighing 2.5 to 3 kg. Anaesthesia was induced by using alphaxolone/alphadolone adminis tered into the radial vein. The animals were intu bated, and positive pressure ventilation with N20/ O2 (70%:30%) was initiated. The femoral arteries and veins were cannulated for the monitoring of arterial blood pressure and arterial blood gas status and for the administration of fluids and drugs, re spectively. Anaesthesia was maintained by using a-chloralose (60 mg/kg), and further supplements of 1-2 ml of a-chloralose (1 % solution) were adminis tered to prevent the return of the corneal reflex. Four cats were used to examine vasomotor reactiv ity under physiologic conditions, and 10 cats were used in the MCA-occlusion study. Arterial blood samples were taken at regular intervals, and the an imals were maintained normocapnic by adjusting the stroke volume; metabolic acidosis was con trolled by the administration of sodium bicarbonate (8. 4% solution). Core temperature was measured by a rectal thermometer, and the temperature was maintained at 370C by means of a heating blanket controlled by the rectal thermometer.
Microapplication studies
Four animals were placed in a stereotactic frame. After a midline incision, the scalp was re tracted and sutured onto a metal ring to form a well over the calvaria. For the microapplication studies, the temporalis muscle was retracted, and a rectan gular craniectomy (2.5 x 1.5 cm) was made over the parietal cortex by using a saline-cooled dental drill. The exposed dura was bathed with mineral oil at 38°C. There was a continuous flow of oil at the rate of � 1 ml/min. With the aid of a stereomicroscope, the dura was excised and then reflected laterally. Bipolar diathermy was used to control bleeding from the dural vessels. The inspired gas mixture was then altered to 02-supplemented air (�25% O2), Measurement of arteriolar calibre. Pial arteriolar calibre was measured by the method of Baez (1966) by using an image splitter linked to a closed-circuit video display system. Individual pial arterioles were viewed through a stereomicroscope, and arte riolar diameter was measured from the degree of shear applied to the image splitter to tangentially appose the two images. The system is calibrated at x 40 and x 70 against threads of known diameter, and this allows the direct measurement of vascular diameter in absolute units (micrometers). The cali bres of cerebral arterioles examined were in the range from 46 to 303 /-Lm (138 ± 62 /-Lm). The vessel diameter was typically measured before insertion of micropipettes, before injection, and after injection of substances; the vessel diameter was monitored over a period of 1-2 min. A detailed description of the surgical preparation and measurement tech nique appeared previously (Robinson and McCul loch, 1990 ).
Administration of drugs. Sharp glass micropi pettes (tip diameter, 10-12 fLm) were vacuum filled with either artificial CSF or drugs dissolved in CSF. The composition of the CSF was Na +, 156 mM; K+, 3 mM; Ca 2 +, 2.5 mM; HC03_, 12 mM; Cl-, 152 mM; with the pH adjusted to 7.2 by aeration with 5% CO2/95% O2, All solutions were prepared freshly for each study. The filled pipettes were stored under mineral oil until required. The sub stances were applied by subarachnoid microappli cation by using a micromanipulator to position the pipettes in the perivascular space around the blood vessel. Small volumes (5 fLl) were delivered by a pressure-ejection system. Individual arterioles were studied on only a single occasion. The perivascular microapplication of CSF elicited a small constrictor response (2.3± 11. 2% of preinjection baseline). Perivascular microapplication of ET-1 (10 nM) was used as the challenge dose, as this is the median effective concentration (ECso) in this preparation .
To investigate the ability of intravenously admin istered PD156707 to gain access to cerebrovascular smooth muscle, PD156707 was dissolved in saline and administered initially as an intravenous bolus (3 fLmollkg) and then by continuous infusion (5 fLmoll kg/h) for 120 min. Perivascular microapplications of ET-l were carried out 15-75 min after the intrave nous administration of PD156707. Arterial blood samples were taken at 30-min intervals to determine drug plasma levels by HPLC.
Focal ischaemia studies
The MCA was exposed in 10 cats by a transor bital approach by a neurosurgeon as described pre viously (Chen et a!. , 1991) . Briefly, the contents of the left orbit were exenterated and the optic fora men enlarged to expose the dura mater and the MCA underlying it. The dura was excised, the trunk of the MCA and its lenticulostriate branches were occluded by using bipolar diathermy, and the artery was divided with microscissors.
Laser Doppler jlowmetry. Two small cranioto mies (3 mm diameter) were drilled overlying the rostral suprasylvian and ectosylvian gyri. Laser Doppler flow probes were placed on the intact dura and attached to the stereotactic frame. Baseline lev els of CBF were determined for � 15 min before the occlusion of the MCA. Thereafter, cerebral perfu sion was assessed continuously for the duration of the study without repositioning of the laser Doppler probes, and the data were stored in a computer (Moor Instruments Ltd. , Axminster, U.K.). In two animals, the suprasylvian laser Doppler probes yielded unstable flow values, particularly after MCA occlusion, and the probes were removed in both animals and data not included in any of the analyses.
Volume of ischaemic damage. Six hours after the occlusion of the MCA, the animals were killed by transcardiac perfusion fixation with FAM (40% formaldehyde, glacial acetic acid, and methanol in a ratio of 1: 1 :8), as described previously (Bullock et a!., 1994) . Briefly, the animals were placed in a su pine position and given heparin. A thoracotomy was performed, and a cannula was introduced into the ascending aorta via the left ventricle. Physio logic saline was infused, at a pressure equivalent to mean arterial pressure of the animals. for 20 s. This was followed immediately by 1. 5 L of FAM fixative at the same pressure. After perfusion, the animals were decapitated, and the heads were stored in the same fixative at 4°C for �12 h. The brains were removed and, after marking the left side of the fore brain with India ink, the hindbrain was detached by a cut through the midbrain, and the cerebral hemi spheres were cut into five equally spaced coronal slices. These slices were embedded in paraffin wax, and sections 7-to 8-fLm thick were cut at 200-fLm intervals throughout the specimens (�150-200 sec tions from each forebrain). The sections were stained by haematoxylin and eosin and by a method combining cresyl-violet and Luxol fast blue. Those sections that corresponded most closely to 16 ste reotactically predetermined coronal planes of the cat brain from the atlas of Reinoso-Suarez (1961) were examined by conventional light microscopy by one of us (D.l. G. ) without prior knowledge of the animal's history. Any abnormalities were charted on scale diagrams, and the area of isch aemic damage in the cerebral hemisphere, cerebral cortex, and caudate nucleus was determined by us ing a computer-based image-analysis system (Quan timet 970, Cambridge Instruments, Cambridge, U. K.). The volumes of ischaemic damage were cal culated from the areas of damage at the different coronal planes and their anteroposterior coordi nates.
In the MCA-occlusion studies, PD156707 (3 fLmollkg) was dissolved in isotonic saline and ad ministered in five animals as a slow intravenous bo lus injection 30 min after occlusion of the MCA. Thereafter, PD156707 was administered as a con tinuous intravenous infusion (5 fLmolikg/h) for the succeeding 330 min. Five additional animals re ceived saline. Samples of arterial blood were taken before administration of the drug, within 5 min of the bolus, and at 60 min intervals thereafter for analysis of drug-plasma levels.
Statistical analysis
Data are presented as mean ± SD. Data from the microapplication studies were analysed by using analysis of variance (ANOY A) followed by Stu dent's t test with Bonferroni correction for multiple comparisons. Cardiovascular and respiratory pa rameters were analysed using two-tailed Student's t test. The laser Doppler flowmetry and pial arterio lar calibre data from the MCA-occlusion studies was analysed by two-way ANOY A with covari ance. The quantitative histopathology data were analysed by one-tailed Student's t test because an a priori decision was made to examine the ability of the drug to reduce the volume of hemispheric isch aemic damage.
RESULTS
Microapplication studies
The mean arterial blood pressure at the outset of the study was 92 ± 9 mm Hg and did not vary significantly from this value. The intravenous injec tion of PD I56707 had minimal effect on mean arte rial blood pressure. The arterial Pco2 was main tained between 26 and 30 mm Hg, and arterial P02 was maintained at > I 00 mm Hg.
The subarachnoid perivascular microapplication of CSF minimally altered pial arteriolar calibre. PD156707 (0.03-3 f.LM) had minimal effect on pial arteriolar calibre (Fig. 1) . The perivascular mi croapplication of ET -1 (10 nM) produced a marked constriction of the pial arterioles examined (36. 12.6% change from premjection baseline). The coapplication of PD156707 (0.03-3 f.LM) with ET-I (10 nM) effected a dose-dependent attenuation of the ET-l-induced vasoconstriction (IC5o � 0.1 f.LM; Fig. 2 ). The intravenous administration of PD156707 (3 f.Lmol/kg bolus + 5 f.Lmol/kg/h infusion) had minimal effect on mean arterial blood pressure. The perivas cular microapplication of ET -1 (10 nM) was carried out 15-75 min after the intravenous administration of PD 156707. The vasoconstrictive response in duced by the perivascular microapplication of ET-l (10 nM) was markedly attenuated (Fig. 3) .
In the microapplication studies, intravenous ad ministration of PD 156707 (3 f.Lmollkg bolus + 5 f.Lmol/kg/h infusion) resulted in drug-plasma levels of 1.9 ± 0.8 f.Lg/ml at 60 min after administration and were maintained at these levels for the duration of the experiment (120 min) (Fig. 4A ).
Focal-ischaemia study
Mean arterial blood pressure at the outset of the study was 95 ± 18 mm Hg in the vehicle-treated group and 93 ± 14 mm Hg in the PDl56707-treated group. The blood pressure did not vary significantly from these values. Arterial PC02 was maintained between 28 and 38 mm Hg, and arterial P02 was maintained at > 100 mm Hg for the duration of the experiment. Core temperature was maintained be tween 36 and 37°C through the course of the exper iment.
In the vehicle-treated animals, cerebral perfusion Data are presented as mean ± SD (n, number of arterioles examined = nine to 13 in each group).
(measured by laser Doppler flowmetry) after MCA occlusion was reduced to 60% of preocclusion base line levels. The vehicle was administered 30 min after MCA occlusion, and the reduction in cerebral perfusion persisted at 60% of preocclusion baseline levels for the experimental period (Fig. 5) . In PDl56707-treated animals, MCA occlusion reduced cerebral perfusion to 40% of preocclusion baseline levels. After the intravenous administration of PD156707 (3 I-lmol/kg bolus + 5 I-lmollkg/h infusion) 30 min after MCA occlusion, there was progressive increase in cerebral perfusion, with the restoration of flow to preocclusion baseline levels at the end of the experimental period (Fig. 5) . Intravenous administration of PD156707 (3 I-lmoll kg bolus + 5 I-lmollkg/h infusion) administered 30 min after MCA occlusion reduced the volume of ischaemic damage in the cerebral hemisphere by 45% (Fig. 6) . PD156707 reduced the volume of isch aemic damage in the cerebral cortex by 59% (Fig.  6) . The volume of ischaemic damage within the cau date nucleus remained unaffected by PD 156707 .
In the MCA-occlusion studies, intravenous ad ministration of PD156707 resulted in drug-plasma levels of 1.7 ± 0.3 I-lg/ml at 60 min after administra tion and did not vary significantly from these levels (Fig. 4B) . of endothelin antagonists (Ziv et aI., 1992; Rubanyi and Polokoff, 1994) . The ability of exogenous ET-l to overwhelm homeostatic mechanisms that main tain CBF, even in the normal CNS. has attracted interest in its role in influencing postischaemic CBF (Robinson et aI., 1990; Fuxe et aI., 1992; Macrae et aI., 1993; Sharkey et aI., 1993) . Endothelin receptor antagonists have no significant effect on cerebral arterial or pial arteriolar calibre in nonpathologic conditions in vivo nor do they alter CBF in normal animals (Foley et aI., 1994; McAuley et aI., 1994; Patel et aI., 1994; Patel et aI., 1995b) . However, topical application of endothelin antagonists in creases the calibre of cortical arterioles in vivo in the ischaemic penumbra after a focal cerebral isch aemic challenge (Patel et aI., 1995a) . The present study demonstrated that the ET A-receptor antago nist PD156707, administered intravenously, in creases CBF to periischaemic areas and reduces the extent of ischaemic damage.
Despite the existence of multiple homeostatic mechanisms to protect blood flow to the brain from compromise, constrictor mechanisms that limit tis sue perfusion to the ischaemic penumbra after ce rebral ischaemia are well recognised (Hossmann et aI., 1973) . A variety of mechanisms for reductions in CBF after focal ischaemia have been proposed. These include vasoconstriction, increased tissue pressure, and luminal obstruction (Teasdale et aI., 1981; Hatashita and Hoff, 1986; Wahl and Schilling, 1993) . However, the precise mechanism for the maintenance of reduced postischaemic CBF is un known. The ability of the endothelin-receptor an tagonist PD156707 to increase cerebral perfusion in dicates a role for endothelin in the regulation of vascular tone and CBF after MCA occlusion. The sources and mechanisms that underlie the increases in endothelin-mediated vascular tone are unclear but increases in tissue and CSF endothelin immu� noreactivities after focal cerebral ischaemia have been reported by a number of groups (Ziv et aI., 1992; Viossat et aI., 1993; Barone et ai., 1994) .
The cellular source of endothelins after a cere brovascular insult is unclear. The presence of en dothelin messenger RNA (mRNA) and release of ET -1 from cerebrovascular endothelial cells have been demonstrated (Yoshimoto et aI., 1990; Saito et aI., 1991; Spatz et aI., 1994) . In brain tissue, both astrocytes and neurons have been reported to pos sess endothelin mRNA (MacCumber et aI., 1990; Ehrenreich et aI., 1991) . The release of endothelin from endothelial cells or from neurons and astro cytes may account for the rapid perturbations in blood vessel calibre after MCA occlusion (MacAr thur et aI., 1994) . The presence of stores of endot- helins in some cells indicates that de novo synthesis of endothelins may not be necessary for the devel opment of the acute effects. There are a number of possible triggers for the release and synthesis of endothelins, including tissue hypoxia (Elton et al., 1992) Time (min) blood pooling in the ischaemic region could trigger the release or synthesis of endothelins (Kurihara et al., 1989; Ohlstein and Storer, 1992) . Products from platelets such as transforming growth factor (TGF)-j3 and platelet-derived growth factor (PDGF) are known inducers of endothelin synthesis and Data are mean ± SO from eight to 10 probes overlying the ectosylvian and suprasylvian gyri in five cats (in each group). The vehicle (saline) was administered 30 min after middle cerebral artery (MCA) occlusion as an intravenous bolus injection, followed by a continuous infusion. PD156707 (3 �mol/kg) was administered as an intravenous bolus injection 30 min after MCA occlusion, followed by a continuous intravenous infusion (5 �mol/kg/h). may also provide a trigger for the release/synthesis of endothelins after an ischaemic insult (Kurihara et a!. , 1989) .
PD156707 per se failed to alter the calibre of nonischaemic feline pial arterioles, indicating that under our experimental conditions, there is minimal endothelin-mediated tone in cerebral resistance vessels. The immediate response after MCA occlu sion is a decrease in cerebrovascular resistance to compensate for the reduction in blood flow. A num ber of investigations have been performed in which vasodilator substances, such as papaverine and ni modipine, increase CBF provided systemic hy potension is avoided (Kazda et a!. , 1982; Brandt et a!. , 1983; Date and Hossmann, 1984; Mohammed et a!. , 1985) . The perivascular microapplication of the calcium channel antagonist nifedipine demonstrated an increase in calibre of postischaemic constricted arterioles, indicating an active vasoconstriction of these blood vessels (Brandt et a!., 1983) . The peri vascular microapplication of endothelin-receptor antagonists on ischaemic arterioles demonstrated an increase in endothelin-mediated vascular tone af ter focal ischaemia (Patel et a!. , 1995a) .
Recent reports demonstrated the efficacy of en dothelin-receptor antagonists in experimental mod els of global ischaemia Ohl stein et a!. , 1994) . Although the role of the endo" thelins as neurotransmitters or neuromodulators has been suggested, the effects of endothelin receptor antagonists per se on neuronal function have not been examined (Gross et a!., 1993; Berrino et a!., 1994) . The mechanism of action of the endo thelin-receptor antagonists in global cerebral isch-J Cereb Blood Plow Metab, Vol. 16, No.5, 1996 aemia is unclear. Few studies have examined the efficacy of endothelin-receptor antagonists in focal cerebral ischaemia Patel et a!. , 1995a) . PD156707 (at a single dose validated for efficacy) reduces the volume of focal ischaemic damage; however, the mechanism of action for this reduction in unclear. It can be speculated that the observed effect may be the result of an enhance ment of periischaemic cerebral perfusion.
The endothelin-receptor antagonists targeted at cerebral resistance blood vessels must penetrate the blood-brain barrier (Edvinsson et a!., 1993; Patel et a!. , 1995b) . The intravenous dose of PD156707 ex amined in this investigation attenuates exogenous ET -I-induced vasoconstriction of nonischaemic ar terioles, demonstrating that bioactive amounts of PD156707 gain access to the adventitial surface of cerebral resistance arterioles. Our unpublished ob servations have indicated that � 12% of the plasma drug level is detectable in the CSF (T. R. Patel, unpublished observations). This validated dose of PD 156707 was subsequently used in the focal ischaemia investigations and demonstrated its abil ity to increase cerebral perfusion and reduce isch aemic damage.
PD156707 is a highly selective antagonist for en dothelin receptors. PD156707 in concentrations � 1 0 f1M did not inhibit the binding of 25 ligands to various neurotransmitter systems, including an giotensin II, neuropeptide Y, and vasoactive intes tinal peptide . In vitro phar macologic data for PD 156707 indicate that this com pound is selective for the ETA-receptor subtype with an IC50 of 0. 3 nM and 420 nM at ETA and ETB receptors, respectively (Doherty et a!., 1995) . In in vitro functional studies, PD156707 demonstrated a 100-fold selectivity for the ETA receptor compared with the ET B receptor . The dose of PD156707 used in our investigations mark edly attenuated the vasoconstrictor response to ET -1 (1 nmol/kg, intravenous bolus) and did not affect the vasodilator response (ET B receptor me diated) elicited by this dose of ET -1, indicating the selectivity of PD 156707 for the ETA receptor (T. R. Patel, unpublished observations).
Previous investigations to characterise the endo thelin-receptor subtypes in feline cerebral arteri oles demonstrated that ETA receptors mediate va soconstriction and ET B receptors mediate vasodila tation (Kobari et a!., 1994; Patel et a!. , 1995c) . The increase in cerebral perfusion in periischaemic ar eas induced by PD156707 is probably due to antag onism of ETA receptor-mediated vasoconstrictions and, perhaps, the unmasking of ET B receptor mediated vasodilatation (Kobari et a!., 1994; Patel et a/., 1995c) . The contribution of ET B receptors to the regulation of perfusion in cerebral ischaemia could be assessed by the selective ET B receptor antagonists and agonists. The efficacy of PD I 56707 in increasing cerebral perfusion in periischaemic ar eas and reducing hemispheric ischaemic damage af ter experimental focal cerebral ischaemia indicates the therapeutic potential of endothelin-receptor an tagonists in the amelioration of ischaemic damage.
